Loading...

Brilliant Violet 605™ anti-mouse CD11c Antibody

Pricing & Availability
Clone
N418 (See other available formats)
Regulatory Status
RUO
Other Names
αX integrin, integrin αX chain, CR4, p150, ITGAX
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
N418_BV605_052112
C57BL/6 mouse splenocytes were stained with I-A/I-E FITC and CD11c (clone N418) Brilliant Violet 605™.
  • N418_BV605_052112
    C57BL/6 mouse splenocytes were stained with I-A/I-E FITC and CD11c (clone N418) Brilliant Violet 605™.
Compare all formats See Brilliant Violet 605™ spectral data
Cat # Size Price Quantity Check Availability Save
117333 125 µL £148
Check Availability


Need larger quantities of this item?
Request Bulk Quote
117334 50 µg £212
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD11c is a 150 kD glycoprotein also known as αX integrin, CR4, and p150. CD11c forms a αXβ2 heterodimer with β2 integrin (CD18). It is primarily expressed on dendritic cells, NK cells, a subset of intestinal intraepithelial lymphocytes (IEL), and some activated T cells. The αXβ2 integrin plays an important role in cell-cell contact by binding its ligands: iC3b, fibrinogen, and CD54.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
Mouse spleen dendritic cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation3, immunohistochemical staining of acetone-fixed frozen sections3, immunofluorescence microscopy5, 9 (Alexa Fluor® 488 conjugated N418 was used for IHC in frozen sections10), and spatial biology (IBEX)22,23.

Application References

(PubMed link indicates BioLegend citation)
  1. Granucci F, et al. 1997. J. Immunol. 159:1794.
  2. Stokes RW, et al. 1998. J. Immunol. 160:5514.
  3. Metlay JP, et al. 1990. J. Exp. Med. 171:1753. (IHC, IP)
  4. Ma XT, et al. 2006. Cancer Research 66:1169.
  5. Chin RK, et al. 2006. J. Immunol. 177:290. (IF)
  6. Cervantes-Barragan L, et al. 2007. Blood 109:1131. (FC) PubMed
  7. Turnquist HR, et al. 2007. J. Immunol. 178:7018. (FC) PubMed
  8. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719. (FC) PubMed
  9. You Y, et al. 2009. J. Immunol. 182:7343. (IF) PubMed
  10. Roland CL, et al. 2009. Mol. Cancer Res. 8:1761. (IHC, FC) PubMed
  11. Wikstrom M, et al.2006. J. Immunol. 177:913. PubMed
  12. Pericolini E, et al. 2008. J. Leukocyte Biol. 83:1286. PubMed
  13. Randall LM, et al. 2008. Infect. Immun.76:3312. PubMed
  14. Fahlen-Yrild L, et al. 2009. J. Immunol. 183:5032. PubMed
  15. Osterholzer JJ, et al. 2009. J. Immunol. 183:8044. PubMed
  16. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  17. Eisenach PA, et al. 2010. J Cell Sci. 123:4182. PubMed
  18. Leppin K, et al. 2014. Invest. Ophthalmol. Vis. Sci. 55:3603. PubMed
  19. Sakai F, et al. 2014. PLoS One. 9:105370. PubMed
  20. Gibbins JD, et al. 2014. Blood. 124:2953. PubMed
  21. White CE, et al. 2015. J Immunol. 194:697. PubMed
  22. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  23. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  24. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Bruand M, et al. 2021. Cell Reports. 36(3):109412. PubMed
  2. Miranda K, et al. 2022. iScience. 25:104994. PubMed
  3. Bergot AS, et al. 2020. J Immunol. 204:1787. PubMed
  4. Pohlmeier L, et al. 2021. Allergy. 76:2030. PubMed
  5. Ozga AJ, et al. 2022. Immunity. 55:82. PubMed
  6. Li T, et al. 2022. J Exp Med. 219: . PubMed
  7. Chaurio RA, et al. 2022. Immunity. 55:115. PubMed
  8. Grégoire C, et al. 2022. Immunity. 55:1216. PubMed
  9. Backlund C, et al. 2022. Proc Natl Acad Sci U S A. 119:e2204078119. PubMed
  10. Montilla A, et al. 2023. Cell Death Dis. 14:16. PubMed
  11. Ivasko SM, et al. 2023. Front Immunol. 13:1023206. PubMed
  12. Wu Q, et al. 2023. Cell Rep. 42:112057. PubMed
  13. Wong Fok Lung T, et al. 2022. Cell Metab. 34:761. PubMed
  14. Li Y, et al. 2023. Adv Mater. 35:e2208923. PubMed
  15. Swan SL, et al. 2023. Front Immunol. 14:1085547. PubMed
  16. Gupta T, et al. 2023. Front Immunol. 14:1044703. PubMed
  17. Houlder E, et al. 2023. Nat Commun. 14:1863. PubMed
  18. Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed
  19. Haensel D, et al. 2023. Nat Commun. 14:2685. PubMed
  20. Hulsebus HJ, et al. 2022. Front Immunol. 13:884719. PubMed
  21. Wong Fok Lung T, et al. 2020. Nat Microbiol. 141:5. PubMed
  22. Minutti CM, et al. 2019. Immunity. 50:645. PubMed
  23. Manivasagam S, et al. 2022. J Immunol. 208:1341. PubMed
  24. Sepe JJ, et al. 2022. JACC Basic Transl Sci. 7:915. PubMed
  25. Chen J, et al. 2022. Nat Commun. 13:6759. PubMed
  26. Stolp B, et al. 2022. Cell Rep. 38:110387. PubMed
  27. Park JG, et al. 2021. iScience. 24(9):102941. PubMed
  28. de Mingo Pulido , et al. 2021. Immunity. 54(6):1154-1167.e7. PubMed
  29. Piper CJM, et al. 2020. Cell Reports. 29(7):1878-1892.e7.. PubMed
  30. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  31. Álvaro de Mingo Pulido et al. 2018. Cancer cell. 33(1):60-74 . PubMed
  32. Xu AQ, et al. 2020. Elife. 9:00. PubMed
  33. Almutairi F, et al. 2021. Front Immunol. 12:772288. PubMed
  34. Zhuo M, et al. 2021. Pigment Cell Melanoma Res. 34:605. PubMed
  35. Mastandrea I, et al. 2022. STAR Protoc. 3:101106. PubMed
  36. Dodagatta-Marri E, et al. 2021. Cell Rep. 36:109309. PubMed
  37. Magod P, et al. 2021. Cell Reports. 36(5):109480. PubMed
  38. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  39. Ellis G, et al. 2015. EMBO Rep. 16: 1203-1218. PubMed
  40. Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed
  41. Wiesner D, et al. 2015. PLoS Pathog. 11:1004701. PubMed
  42. Ratitong B, et al. 2021. Cell Reports. 35(7):109139. PubMed
  43. Li J, et al. 2020. Cancer Discov. . PubMed
  44. McAlpine CS, et al. 2021. Nature. 595:701. PubMed
  45. Tomlinson KL, et al. 2021. Nat Commun. 12:1399. PubMed
  46. Forbester JL, et al. 2020. J Virol. 94:. PubMed
  47. Aegerter H, et al. 2020. Nat Immunol. 0.975694444. PubMed
  48. Li J, et al. 2020. Cancer Immunol Res. 0.529166667. PubMed
  49. Lagares D, et al. 2017. Sci Transl Med. 9:eaal3765. PubMed
  50. Wang ECE, et al. 2019. Cell Stem Cell. 24:654. PubMed
  51. Pereira JA, et al. 2020. Hum Mol Genet. 29:1253. PubMed
  52. Li J, et al. 2018. Immunity. 49:178. PubMed
  53. Riquelme SA, et al. 2020. Cell Metabolism. 31(6):1091-1106.e6. PubMed
  54. Sutherland TE, et al. 2021. Frontiers in Immunology. 12:715209. PubMed
  55. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  56. Guo Y, et al. 2020. Cell Host & Microbe. 28(1):104-116.e4.. PubMed
  57. Acker KP, et al. 2019. iScience. 19:281. PubMed
  58. Medler TR et al. 2018. Cancer cell. 34(4):561-578 . PubMed
  59. Macdougall CE et al. 2018. Cell metabolism. 27(3):588-601 . PubMed
  60. Pennock ND, et al. 2018. J Immunother Cancer. 0.318055556. PubMed
  61. Jorapur A, et al. 2022. PLoS Pathog. 18:e1010200. PubMed
  62. Becker W, et al. 2021. J Crohns Colitis. 15:1032. PubMed
  63. Olson GS, et al. 2021. Cell Reports. 35(9):109195. PubMed
  64. Dewi IMW, et al. 2021. Cell Reports Medicine. 2(5):100289. PubMed
  65. Pundir P, et al. 2020. Cell Host & Microbe. 26(1):114-122. PubMed
  66. Kyburz A, et al. 2019. J Allergy Clin Immunol. 143:1496. PubMed
  67. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  68. Spix B, et al. 2022. Nat Commun. 13:318. PubMed
  69. Gamrekelashvili J, et al. 2021. Bio Protoc. 11:e4007. PubMed
  70. Hu X, et al. 2021. JCI Insight. 6:. PubMed
  71. Muri J, et al. 2020. eLife. 9:e53627.. PubMed
  72. Dangaj D, et al. 2019. Cancer Cell. 35:885. PubMed
  73. Engblom C, et al. 2017. Science. 358:6367. PubMed
  74. Teo TH, et al. 2018. Nat Commun. 9:3905. PubMed
  75. Dallari S, et al. 2021. Cell Host Microbe. 29(6):1014-1029.e8. PubMed
  76. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  77. Lang JF et al. 2019. Nat Commun. 10(1):3415 . PubMed
  78. Nicolas-Boluda A, et al. 2021. eLife. 10:00. PubMed
  79. Santopaolo M, et al. 2021. Front Immunol. 609406:12. PubMed
  80. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  81. Hackstein CP, et al. 2022. Nat Commun. 13:7472. PubMed
  82. Fleskens V, et al. 2019. Cell Rep. 26:3600. PubMed
  83. Koyama M et al. 2019. Immunity. 51(5):885-898 . PubMed
  84. Ehrens A, et al. 2021. Cell Reports. 34(2):108621. PubMed
  85. Phadke MS, et al. 2021. Cancer Immunol Res. 9:554. PubMed
  86. Rappe JCF, et al. 2021. J Exp Med. 218:. PubMed
  87. Gardner A, et al. 2022. J Immunother Cancer. 10:. PubMed
  88. Subramanian S, et al. 2022. Nat Immunol. 23:458. PubMed
  89. Kastenschmidt JM, et al. 2021. Cell Rep. 35:108997. PubMed
  90. Fearon AE, et al. 2021. iScience. 24:103143. PubMed
  91. Celias DP, et al. 2022. STAR Protoc. 3:101464. PubMed
  92. Goddery EN, et al. 2021. Front Immunol. 12:726421. PubMed
  93. Allman W, et al. 2015. Proc Natl Acad Sci U S A. 112: 4094 - 4103. PubMed
  94. McGinley AM, et al. 2020. Immunity. 52(2):342-356. PubMed
RRID
AB_11204262 (BioLegend Cat. No. 117333)
AB_11204262 (BioLegend Cat. No. 117334)

Antigen Details

Structure
Integrin α-chain, associates with integrin β2 (CD18), 150 kD
Distribution

Dendritic cells, NK cells, intestinal intraepithelial lymphocytes (IEL), some activated T cells

Function
Cellular adhesion
Ligand/Receptor
iC3b, fibrinogen
Cell Type
Dendritic cells, Epithelial cells, NK cells, T cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity, Neuroscience, Neuroscience Cell Markers
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen Facts Book Academic Press.
2. Springer TA. 1994. Cell 76:301.
3. Lopez-Rodriguez C, et al. 1996. J. Immunol. 156:3780.

Gene ID
16411 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD11c
Specificity Alt (DOES NOT SHOW ON TDS):
CD11c
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD11c on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD11c Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD11c N418 FC
Biotin anti-mouse CD11c N418 FC,IHC-F
FITC anti-mouse CD11c N418 FC
PE anti-mouse CD11c N418 FC
Purified anti-mouse CD11c N418 FC,CyTOF®,IP,IHC
Alexa Fluor® 488 anti-mouse CD11c N418 FC
Alexa Fluor® 647 anti-mouse CD11c N418 FC,IHC,ICC,3D IHC
PE/Cyanine5 anti-mouse CD11c N418 FC
PE/Cyanine7 anti-mouse CD11c N418 FC
Brilliant Violet 605™ anti-mouse CD11c N418 FC
Alexa Fluor® 700 anti-mouse CD11c N418 FC
Pacific Blue™ anti-mouse CD11c N418 FC
APC/Cyanine7 anti-mouse CD11c N418 FC
PerCP/Cyanine5.5 anti-mouse CD11c N418 FC
PerCP anti-mouse CD11c N418 FC
Brilliant Violet 421™ anti-mouse CD11c N418 FC,IHC
Brilliant Violet 570™ anti-mouse CD11c N418 FC
Brilliant Violet 785™ anti-mouse CD11c N418 FC
Brilliant Violet 510™ anti-mouse CD11c N418 FC
Brilliant Violet 650™ anti-mouse CD11c N418 FC
Purified anti-mouse CD11c (Maxpar® Ready) N418 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD11c N418 IHC-F,3D IHC
PE/Dazzle™ 594 anti-mouse CD11c N418 FC
Brilliant Violet 711™ anti-mouse CD11c N418 FC
APC/Fire™ 750 anti-mouse CD11c N418 FC
TotalSeq™-A0106 anti-mouse CD11c N418 PG
Brilliant Violet 750™ anti-mouse CD11c N418 FC
TotalSeq™-B0106 anti-mouse CD11c N418 PG
TotalSeq™-C0106 anti-mouse CD11c N418 PG
KIRAVIA Blue 520™ anti-mouse CD11c N418 FC
Spark Blue™ 550 anti-mouse CD11c N418 FC
Spark NIR™ 685 anti-mouse CD11c N418 FC
Spark UV™ 387 anti-mouse CD11c N418 FC
Spark Red™ 718 anti-mouse CD11c N418 FC
Spark Blue™ 515 anti-mouse CD11c N418 FC
PerCP/Fire™ 806 anti-mouse CD11c N418 FC
Spark PLUS UV395™ anti-mouse CD11c N418 FC
Spark Blue™ 574 anti-mouse CD11c (Flexi-Fluor™) N418 FC
Go To Top Version: 2    Revision Date: 10/21/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account